BLAORALCAPSULE, DELAYED RELEASE
Approved
May 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
PERTZYE (pancrelipase) by AbbVie is lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltotriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas. First approved in 2012.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERTZYE is an oral delayed-release pancreatic enzyme replacement therapy containing lipases, proteases, and amylases that replicate the digestive function of the pancreas. It is indicated for patients with pancreatic insufficiency who cannot adequately digest fats, proteins, and carbohydrates. The product works by catalyzing hydrolysis of dietary macronutrients in the small intestine, enabling normal nutrient absorption.
$0.007BPart D
PeakProduct is at peak lifecycle stage with modest Part D spending (~$7M in 2023), indicating a mature, stable franchise with focused commercial support needs.
Mechanism of Action
lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltotriose in the duodenum and proximal small intestine, thereby…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
Started Dec 2020
36 enrolled
Pancreatic Adenocarcinoma
A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
Started Feb 2020
1 enrolled
Exocrine Pancreatic Insufficiency (EPI)
A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency
Started Aug 2008
40 enrolled
Exocrine Pancreatic InsufficiencySteatorrheaMalabsorption Syndromes+1 more
A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)
Started Jul 2008
13 enrolled
Exocrine Pancreatic InsufficiencyPancreatitis, ChronicSteatorrhea+1 more
Worked on PERTZYE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.